Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | GAPDH | P04406 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | STAT6 | P42226 | 1/20 | 0.63 |
| ▸ | PI4KA | P42356 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.63 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.63 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.63 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754461 | 1.00 | ADORA1 (0.64) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL9011463 | 0.99 | ADORA1 (0.62) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL9011483 | 0.99 | ADORA1 (0.62) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL9011485 | 0.99 | ADORA1 (0.62) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL9011465 | 0.99 | ADORA1 (0.62) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL8938091 | 0.99 | ADORA1 (0.62) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL8938093 | 0.99 | ADORA1 (0.62) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL5977911 | 0.93 | ADORA3 (0.67) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL5977903 | 0.93 | ADORA3 (0.67) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL6261501 | 0.88 | ADORA2A (0.67) | ADORA1ADORA3SLC29A1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266706-A1 | Cross-linked oligomeric compounds and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040147470-A1 | Cross-linked oligomeric compounds and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004044131-A2 | CROSS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-5719271-A | HYBRIDS; GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5543507-A | BONDING STRANDS OR ONE STRAND AT DIFFERENT SITES; RNA MIMICS FIXED IN SPATIAL CONFORMATION; NUCLEASE RESISTANT MIMICS OF BINDING RECEPTORS FOR NUCLEIC ACID-BINDING PROTEINS; 5-LIPOXYGENASE INHIBITORS; DIAGNOSIS; ANALYZING | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0635023-A4 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147470-A1 | Cross-linked oligomeric compounds and their use in gene modulation | SNRPE, DCLRE1A, PHAX | ADORA1 4073/4885ADORA3 4064/4885SLC29A1 1544/4885 |
| US-20040266706-A1 | Cross-linked oligomeric compounds and their use in gene modulation | SNRPE, DCLRE1A, PHAX | ADORA1 4073/4885ADORA3 4064/4885SLC29A1 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.